PHILADELPHIA (WPVI) -- Researchers at the University of Pennsylvania are reporting early success with a Zika vaccine, one that could protect people with a single dose.
Other Zika vaccines in the works use either a virus or DNA to get into cells.
However, the Penn team uses RNA - a molecule that acts as a messenger in cells.
It's much more efficient than DNA in getting into cells.
"If you inject DNA, you find about 1 in 100 cells actually take it up. When you inject RNA, 80, 90-plus percent of the cells take it up. So it's much more efficient," said Dr. Drew Weissman.
In lab animals, it only took one dose - and a much smaller dose - to create immunity.
That would make it much easier to vaccinate big populations, especially in developing nations where it could be hard to get people back for a second dose.
Penn's vaccine may also be substantially cheaper and faster to produce.
Human trials could begin in 12 to 18 months.
University of Pennsylvania developing Zika vaccine
More TOP STORIES News